Selected Grants
Short Title Phase 3 Sonrotoclax + Zanubrutinib compared with Ven + Obinutuzumab in Patients untreated CLL
Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2024 - 2029A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton?s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Clinical TrialPrincipal Investigator · Awarded by Nurix Therapeutics, Inc. · 2024 - 2029An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies
Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2023 - 2028A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects with Relapsed or Refractory B-cell Malignancies
Clinical TrialPrincipal Investigator · Awarded by Newave Pharmaceutical, Inc. · 2021 - 2026AN OPEN LABEL PHASE Ia/b DOSE ESCALATION FOLLOWED BY DOSE EXPANSION SAFETY AND TOLERABILITY TRIAL OF CAP 100, A HUMANIZED C C CHEMOKINE RECEPTOR 7 ANTIBODY, ADMINISTERED AS MONOTHERAPY IN SUBJECTS WITH R/R CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical TrialPrincipal Investigator · Awarded by Catapult Therapeutics BV · 2021 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026A Phase 3, Randomized study of Zanubrutinnig (BGB-3111) compared with Ibrutinig in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical TrialPrincipal Investigator · Awarded by BeiGene, Ltd · 2019 - 2025A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
Clinical TrialPrincipal Investigator · Awarded by ArQule, Inc. · 2019 - 2024An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2019 - 2024A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2015 - 2024BGB-3111-304 An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical TrialPrincipal Investigator · Awarded by BeiGene, Ltd · 2018 - 2024A Phase 1, Open-label, study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies after failure of prior standard therapies
Clinical TrialPrincipal Investigator · Awarded by MEI Pharma, Inc. · 2018 - 2023Phase 1a/1b Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, CTRM-505 and DTRM-555, in Patients with Chronic Lymphocytic Leukemia or Other B-Cell Lymphomas
Clinical TrialPrincipal Investigator · Awarded by Zhejiang DTRM Biopharma Co.Ltd. · 2018 - 2023An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2018 - 2023DFCI Obinutuzumab and Ibrutinib Protocol # 15-283
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2017 - 2022A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2016 - 2022A Multi¿Center, Open¿Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2016 - 2022A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2016 - 2022Phase III study of ACP-196 vs Ibrutinib in High Risk CLL
Clinical TrialPrincipal Investigator · Awarded by Acerta Pharma · 2016 - 2022Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts.
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2015 - 2022Exercise training to promote improved immune resilience in adults with chronic lymphocytic leukemia - a randomized control trial
Clinical TrialMentor · Awarded by American Society of Hematology · 2020 - 2021The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcomes in the Era of the Novel Agents
ResearchCo-Mentor · Awarded by American Society of Hematology · 2020 - 2021A Phase 1 study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refractory CLL or Richter's transformation of CLL
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2020 - 2021Novartis: CVAY736Y2102 Ph1b VAY736 and Ibrutinib patients with CLL on Ibrutinib therapy
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2021TP-0903-102 A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Clinical TrialPrincipal Investigator · Awarded by Tolero Pharmaceuticals, Inc · 2019 - 2020A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronie Lymphocytic Leukemia with 17p Deletion
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2014 - 2019Screening protocol to determine high risk cytogenetic features in previously treated CLL
Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2016 - 2017A Phase II Study of PNT2258 in Patients with Richter's Transformation (RT).
Clinical TrialPrincipal Investigator · Awarded by ProNAi Therapeutics, Inc. · 2016 - 2017MedImmune CD-ON-CAT-8015-1053
Clinical TrialPrincipal Investigator · Awarded by MedImmune, Inc. · 2015 - 2017A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia GS-US-312-0123
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2014 - 2017A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL
ResearchPrincipal Investigator · Awarded by Lymphoma Research Foundation of America · 2014 - 2016A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2013 - 2015External Relationships
- AbbVie, Inc.
- Alliance for Clinical Trials in Oncology
- ArQule/Merck
- AstraZeneca
- BeiGene
- CLL Society
- Clinical Care Options
- DTRM Biopharma
- Dava Oncology
- Genentech, Inc (Roche Holding)
- Juno/celgene/BMS
- NCCN
- Newave Pharma
- Pharmacyclics
- Prime Oncology
- TG Therapeutics
- WebMD/Medscape
- catapult
- nurix
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.